NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi
Conditions: Diabetes Mellitus, Type 2
Interventions: insulin glargine (U300)
Countries: France
Primary Objective: The primary objective is to describe the effect of insulin glargine (U300) in type 2 diabetes mellitus (T2DM) patients uncontrolled with their current basal insulin therapy and eligible for basal switching, according to the Physician decision, on glycated hemoglobin (HbA1c) improvement. Secondary Objectives: * Evolution of fasting plasma glucose * Evolution of insulin dose and body weight * Hypoglycemia incidence * Safety * Patients satisfaction when they change their insulin for HOE901-U300
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion criteria : * Type 2 diabetic adult patients treated with basal insulin, with or without oral anti-diabetic agents, with or without glucagon-like peptide-1 (GLP-1) receptor agonist * HbA1c \> 7.5% Exclusion criteria: * Patients with high dose of insulin (\>1.2 U/kg) * Use of prandial insulin * Change of dose of antidiabetic drugs within the last 8 weeks * Use of systemic glucocorticoids during at least 2 weeks in the last 12 weeks The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
- Alençon, France
- Alès, France
- Amiens, France
- Amilly, France
- Bagnols-sur-Cèze, France
- Bar-le-Duc, France
- Besançon, France
- Béthune, France
- Bondy, France
- Brest, France
- Brest, France
- Cahors, France
- Cannes, France
- Chambéry, France
- Châlons-en-Champagne, France
- Cholet, France
- Clermont-Ferrand, France
- Cognac, France
- Colmar, France
- Contamines Sur Arve, France
- Coudray, France
- Dijon, France
- Eaubonne, France
- Étampes, France
- Grenoble, France
- La Roche-sur-Yon, France
- La Rochelle, France
- La Seyne-sur-Mer, France
- Lamagistère, France
- Le Chesnay, France
- + 55 more on CT.gov